Physiological events involved in nociception and pain perception are examined. Substance P could be a primary afferent transmitter of certain nociceptive information. Transmission of this information can be modulated within the spinal cord by intrinsic and descending mechanisms. The intrinsic mechanism involves inhibitory opiate effects within substantia gelatinosa. Centres for descending systems are located in medulla and periaqueductal gray matter. They are activated by exogenous narcotic agonists, and by regional connections. Descending inhibitory pathways are serotonergic and noradrenergic. GABA and glycine are also possibly involved in antinociception. Narcotics have been shown to produce analgesia when administered to the intrathecal or epidural spaces of humans. These routes are still experimental. The place of clinical modification of transmitter system is discussed, but no conclusions or recommendations can be made at this early stage.
Pain is "an unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in terms of such damage".1 Pain may be relieved by reducing sensory input from damaged tissue, modulating transmission through the central nervous system, or altering emotional responses to such actual or perceived input. The experience of pain cannot be measured directly: precise studies are therefore not possible.
Nociception is perception of noxious (tissuedamaging) stimuli. Experimental noxious stimuli can be quantitated and responses measured. Anatomical and physiological substrates of nociception have been studied extensively.2,3 With increasing knowledge of nociceptive mechanisms, rational advances in pain therapy will become possible.
The gate th eory4 of pain stimulated a resurgence of interest and research into pain mechanisms. It was unable to explain all pain phenomena, and was based on admittedly incomplete contemporary knowledge of physiology. WalP has made a general restatement of the theory, which summarises present concepts:
(1) Information about the presence of injury is transmitted to the central nervous system by peripheral nerves. Certain small diameter fibres (Ad and C) respond only to injury, while others with lower thresholds increase their discharge frequency if the stimulus reaches noxious levels. (2) Cells in the spinal cord or fifth nerve nucleus which are excited by these injury signals are also facilitated or inhibited by other peripheral nerve fibres which carry information about innocuous events. (3) Descending control systems originating in the brain modulate the excitability of the cells which transmit information about injury.
This theory emphasises that perception of noxious stimuli (and pain) depends not only on peripheral stimulation and transmission but also on modulation occurring in spinal cord and higher structures. Pain (and pain control) must be considered in terms of both an afferent limb ("pain pathways") and descending pathways which modify the sensory message.
This review will report recent significant advances in understanding physiological and pharmacological processes within spinal cord and brain responsible for transmission and modulation of nociceptive information. Five broad topics will be considered: (1) pharmacology of primary afferent transmissIon; (2) mechanisms of opiate analgesia; (3) other analgetic* systems; (4) clinical applications of recent advances; and (5) possible further advances in anaesthesia and pain management.
PHARMACOLOGY OF PRIMARY AFFERENT

TRANSMISSION
An unanswered question is whether pain is a specific sensation. s Information about noxious events is carried in some (but not all) A <5 and C fibres in peripheral nerves. 6 ,7 Certain cells in dorsal horn of spinal cord respond preferentially or exclusively to nociceptive input. 2 ,8 WalP accepted that the term "specificity" was appropriate in a diagnostic sense: under defined conditions there may be "a fixed and specific relation between stimulus and response". The term was unacceptable if used in a "predictive prognostic" sense: if impulses are detected in a particular nerve, it is not possible to predict resulting sensations.
Substance P, an undecapeptide, may play a part in nociceptive and primary afferent transmission. It is present in presumed sensory terminals in skin.9 Skin terminals may be initially stimulated and then depleted of substance P by treatment (of a blister base) with capsaicin, a homovanillic acid derivative. lO ,lI Pain was caused by the initial application of capsaicin, while subsequent applications were painless. This implied that substance P may have been necessary for activation of certain nociceptors. Substance P and somatostatin have also been shown in axons and cell bodies of primary afferents in dorsal root ganglia. 12 ,13 "'Oxford English Dictionary: Anaesthesia -anaesthetic, hence analgesiaanalgetic.
Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 Dorsal rhizotomy caused almost total loss of substance P in dorsal horn. 14 ,IS It has also been shown to be stored by some trigeminal ganglion neurones, and possibly released at axon terminals in medulla and skin.9 Substance P was not demonstrated in dorsal column nuclei,16 suggesting that it was not associated with terminals of large (non-nociceptive) primaryafferents.
Substance P has been shown to cause excitation of certain spinal neurones. 17 More significantly, H enry 18 showed that iontophoresis of substance P produced excitation of spinal cord cells excited by noxious thermal stimuli to skin, with little effect on other cells. Substance P has been shown to be released by potassium from slices of trigeminal nucleus and spinal cord in vitro. 19 This release was inhibited by an en kephalin (see below). Clearest evidence that substance P is involved in thermal nociception has been produced by Yaksh et al. 20 A single lumbar intrathecal injection of capsaicin in rats produced severe temporary agitation with biting and scratching caudal areas. Recovery was apparently complete, with no gross abnormality of motor function, proprioception or light touch sensitivity. However, the animals were analgetic to noxious thermal and chemical stimuli. This analgesia persisted for as long as 20 weeks. There was no apparent change in response to noxious mechanical stimuli. Analgetic doses of intrathecal capsaicin produced a 55070 reduction in the concentration of substance P in the lumbar spinal cord. Additional evidence for a role of substance P in nociception was provided by Jessell et al. 21 Lumbar spinal cord of anaesthetised rats and cats was super fused with an artificial CSF. Low levels of substance P, somatostatin and neurotensin were detected in the absence of any evoking stimulus. Addition of potassium produced increases in release of these peptides: substance P, 4.0 ± 0.6 fold; somatostatin, 2.8 ± 1.0 fold; and neurotensin, 1.8 ± 0.4 fold. Capsaicin added to the superfusate produced a dose-dependent increase in the release of substance P (9.1 ± 2.6 fold) and somatostatin (3.9 ± 1.6 fold), but not neurotensin. Stimulation of sciatic nerves at intensities high enough to activate A <5 and C fibres resulted in three-fold increases in substance P and somatostatin release. Such increase was reduced by systemic morphine and restored by systemic naloxone. These authors pointed out that very little is known about the post-synaptic actions of these peptides. It is possible that they act as neuromodulators 22 rather than neurotransmitters. It is also possible that the transmitter of one (or more) populations of sensory afferents involved in nociception may be inhibitory. Other peptides may have a role in primary afferent transmission: neurotensin has been shown to excite dorsal horn neurones (lamina 1-111);23 vasoactive intestinal peptide may have a role;24 and cholecystokinin is present in periaqueductal gray matter. 25 It is evident that mechanisms of primary afferent transmission of nociceptive information are unresolved. It is therefore not yet possible to devise rational methods of modulating such input at the stage of transduction or transmission to the secondorder neurones in the spinal cord.
MECHANISMS OF OPIATE ANALGESIA
Opium has been used for millenia to obtund pain. It is only recently that sites of actions of opiate analgetics have been elucidated. 26 Opiate-specific binding sites have been shown throughout the central nervous systemy,28 Highest concentrations were reported in regions related to nociception; dorsal horn, certain medullary nuclei, periaqueductal gray matter. Microinjections of morphine into certain brain sites of primates produced behavioural analgesia. 29 The most active sites were in periaqueductal gray matter of the midbrain, but certain medullary areas were also active. Similar microinjections in rats blocked the tail flick, presumed to be a spinal reflex. Subsequent anatomical, physiological and pharmacological studies in several laboratories showed that this analgesia was mediated via descending serotonergic and/or nor adrenergic pathways.3D,31 Narcotic agonists also have direct effects on spinal neurones, depressing cells responding to noxious peripheral stimuli. 32 ,33 Administration of narcotics into the lumbar intrathecal space of animals produced behavioural analgesia. 34 These neuronal and behavioural effects fulfilled criteria for opiate receptor activation: dose-dependency, stereospecificity, naloxone reversibility and a well-defined structure-activity series. The locus of action in the spinal cord was defined as within the substantia gelatinosa by Duggan, Hall and Headley. 33 Endogenous opiate-like peptides had been isolated contemporaneously. 35, 36 Certain of these pentapeptides (enkephalins) and their parent polypeptides (endorphins) produced analgesia when administered into cerebral ventricles or spinal intrathecal space of animals. 37 Dose-response curves and dose-ratio plots of morphine, methionine-enkephalin, methionine-enkephalin amide and D-alanineen kephalin amide, suggested a common locus of action. Their distribution was similar to the previously described areas of high opiate binding; in particular, dorsal horn, medullary nuclei and periaqueductal gray.
Relationships between primary afferent terminals and opiate inhibition are yet to be determined. Although substance P release has been shown to be blocked by opiates, 19 it has also been shown that certain en kephalin effects in the substantia gelatinosa were independent of excitation by substance P. 38 The latter authors suggest that either substance P was not the transmitter released from primary afferents by noxious skin stimulation, or en kephalin could act at sites remote from terminals of nociceptive afferents.
The nemesis of opiate action is the tolerance which develops. It is not proposed to review exhaustively the questions of tolerance, dependence and withdrawaP9 in this paper. A degree of tolerance has been described after a single intracerebral and intraperitoneal injection of morphine in rats.4D Evidence for this was the observation that a second identical dose of morphine 6-24 hours after the first did not produce as much analgesia as the initial dose. Physical dependence has also been demonstrated after a single injection of opiate. 41 This was implied from the induction by naloxone of withdrawal signs in the experimental animals. Withdrawal signs have been observed in single neurones and isolated organs. 42 On the other hand, there has been a report that rats with chronic pain may fail to develop tolerance to narcotic analgesia. 43 New evidence suggests that development of physical dependence on morphine in animals (measured by naloxone-induced withdrawal) may be prevented by treatment with certain Anaesthesia and Intensive Care, Vol. VIII, No. 3, August, 1980 dipeptides. 44 There are profound implications of this observation. It might be possible, for example, to maintain clinical analgesia with a constant dosage of narcotic, without risk of addiction or withdrawal. More research will be needed to clarify this question.
OTHER ANALGETIC SYSTEMS
Electrical stimulation of periaqueductal gray and certain medullary nuclei, or with microinjections of morphine, activates descending noradrenergic and serotonergic pathways.3l Certain other amino acids may have central inhibitory and analgetic effects. 45 
Serotonin
Manipulation of brain and spinal cord serotonin levels has been shown to alter pain responses (see Table 11 of Messing and Lytle, 1977) .30 Inferred increases in serotonin were accompanied by reductions in pain responses. Changes in serotonergic neurotransmission also caused changes in apparent potency of morphine, with increases in serotonin potentiating morphine analgesia (their Table   Ill ).
Direct application of serotonin to the spinal cord of intact rats was shown to cause behavioural analgesia. 46 More complete studies showed that analgesia resulting from this intrathecal injection was antagonised by purported serotonin antagonists, methysergide and cyproheptadine. 47 Analgesia was increased by pretreatment with monoamine oxidase inhibitors or serotonin uptake blockers. Naloxone had no effect, implying that an opiate link was not involved in this serotonin analgesia.
However, intrathecal administration of methysergide blocked analgesia resulting from microinjections of morphine into periaqueductal gray matter. 24 This provided additional corroboration for a serotonergic link in opiate analgesia. In addition, serotonin has been shown to be released from spinal cord after periaqueductal morphine injection. 48 
Noradrenaline
Descending monoaminergic pathways have been well documented, and effects on various brain systems have been defined.
Pharmacology of central inhibition was reviewed by Duggan. 45 Activation of spinal terminals of bulbo-spinal catecholamine pathways exerts inhibitory effects both on
Anaesthesia and Intensive Care, Vol. VllI, No. 3, August, 1980 dorsal and ventral horn neurons. 49 In particular, noradrenaline (and serotonin) selectively reduced nociceptive responses of certain cat dorsal horn neurones when applied iontophoretically. 50 Direct application of noradrenaline (and other a-adrenergic agonists, including clonidine) to the surface of lumbar cord of rats and cats produced behavioural analgesia. 49 ,5l There were no other apparent changes apart from antinociception. The effect was not antagonised by naloxone, serotonin antagonists, or non-specific vasodilators. Thus, there is strong evidence from a number of sources that descending monoamine pathways modulate nociceptive input within the dorsal horn via a-adrenergic receptors.
Amino Acids and Other Inhibitors
Dorsal horn neurones have been shown to be inhibited by GABA (y-aminobutyric acid),52 glycine,53 cyclic GMP ,54 glutamic acid,55 neurotensin 56 and somatostatin. 57 Physiological roles for these transmitters/neuromodulators has yet to be determined. 22 It is interesting to note than lanthanum was shown to produce analgesia, with cross-tolerance with morphine. 58 Intraventricular (cerebral) calcitonin was also shown to produce analgesia. 59 Baclofen, (f3-chlorophenyl-GABA) has been shown to produce analgesia when microinjected into certain supraspinal sites. 60 It also produced a dose-dependent, stereospecific analgetic effect after lumbar intrathecal injection in rats and cats, not antagonised by naloxone,6l It was reported that morphine, serotonin and baclofen have synergistic analgetic effects, suggesting that they might act at different sites in the dorsal horn. 62 Modulation of nociceptive input and transmission is a complex phenomenon, with apparent involvement of at least three intrinsic systems (en kephalin, serotonin and noradrenaline). It is possible to construct a theoretical model of the nociceptive system (Figure 1) . This model is derived from information presently available, and will doubtless be modified or corrected as further knowledge of this system is obtained. However, it can act as a basis for discussion of potential pharmacological intervention. It is important to recognize that the model contains both 
CLINICAL ApPLICATIONS
Using the model of the nociceptive circuit above, predictions of clinical applications become possible (and some traditional therapies are justified). Perturbations within the circuit may result in antinociception/ analgesia. This is only one aspect of pain relief: questions of human anguish and suffering cannot be discussed with this simple model, although they might be the most important aspects of chronic pain syndromes.
Pain is subjective. Estimation of quality, quantity and emotional content is difficult, even with sophisticated questionnaires requiring high fluency in English. 63 ,64,65 It is therefore difficult or impossible to obtain valid, reliable and objective measurements of experimental or clinical pain and analgesia. Electrophysiological and biochemical measures are crude and non-specific at present.
Electrical Stimulation
A prediction of the gate control theory of pain was that stimulation of large diameter peripheral nerve fibres should effect some blockade of nociception. Consequently, transcutaneous electrical stimulation of afferent peripheral nerves was attempted. 66 This may have some place in the management of acute and chronic pain of peripheral originY However, a placebo effect is present with this technique. 6H Dorsal columns consist largely of ascending large primary afferents, with collaterals to dorsal horns. Stimulation of dorsal columns has been attempted with transcutaneous 69 or implanted electrodes. 70 Electrical stimulation of various brain sites has been attempted in efforts to produce analgesia. In 1969 Reynolds 71 showed that such stimulation of periaqueductal gray matter could produce profound analgesia in rats. This observation was later applied to clinical cases by Hosobuchi, Adams and Linchitz in 1977. 72 Such analgesia had been reported to have been reversed by naloxone, implying an opioid link. However, the place of such heroic intervention in pain management has been questioned. 73 available. 26 ,36 Narcotics produce analgesia in part by activating supraspinal mechanisms which consequently produce descending modulation of spinal cord transmission. The relative contribution of this narcotic action to the total amount of analgesia is not known.
PHARMACOLOGY OF THE NOCICEPTIVE
Spinal narcotic analgesia:
Yaksh and Pert1 4 ,75 showed that administration of very small quantities of narcotics directly into the lumbar subarachnoid space of rats produced dose-dependent, stereospecific, naloxone-reversible analgesia. This was "pure" analgesia as measured by spinal reflex and complex behavioural responses to a variety of noxious stimuli. There was no detectable motor impairment, and no sensory alteration to non-noxious stimuli.
Wang, Nauss and Thomas (1979)16 conducted a double-blind clinical trial of lumbar intrathecal morphine in patients with severe intractable pain of pelvic cancer. They reported that 0.5-1.0 mg morphine by this route was able to produce 12-24 hours pain relief. A similar result was described after cervical intrathecal administration of 0.5 mg morphine. 77 Although this method of narcotic administration is highly effective, little is known about its pharmacokinetics or pharmacodynamics. Initial studies of blood and CSF levels have been reported by Kaiko et al. 78 Attempts have been made to improve the duration and extent of analgesia by using hyperbaric solutions. There is a potential for respiratory depression if narcotic should spread to the brain stem.79 Two clinical cases of such respiratory depression have been recorded. 80 The full potential of this route has yet to be realised.92 Its place in the diagnosis and management of acute and chronic pain is also unknown.
Intrathecal administration of drugs has intrinsic problems in clinical Practice (infection, spinal headache, cord damage, local trauma and discomfort from repeated punctures), and it was logical to attempt to use the epidural route. Initial animal studies suggested that analgesia produced by epidural narcotics was less potent and of shorter duration than that by intrathecal administration. 81 Preliminary clinical studies 82 reported that analgesia produced by epidural morphine ( Epidural pethidine was shown to produce high CSF levels. 83 Onset of analgesia occurred when CSF pethidine reached a concentration similar to the blood level producing analgesia with systemic administration (0.5 mg/l).
Epidural pethidine analgesia was without detectable change in motor, sensory or sympathetic activity. However, it was widely variable in duration (4.5-20 hours). Torda 84 has also reported a series of cases of epidural morphine analgesia. The final place of this technique must await the results of further, properly conducted trials.
Enkephalins/endorphins:
Various endogenous and synthetic opioid peptides have been shown to produce analgesia in a number of animal models. 35 ,85 They have been administered by intravenous, intrathecal and oral routes. 86 ,87 Tolerance and crosstolerance with other narcotics also develops. Once again, it is too early to predict the final place of such compounds in clinical practice. In view of the evidence available about opiate receptors, their specific natures, and the availability of pure agonists and antagonists, there can be no argument for the use of drugs with mixed agonist/antagonist activity (e.g., pentazocine, buprenorphine). There is no evidence that equianalgetic doses of such drugs are less likely to produce tolerance/dependence than pure agonists. Preliminary data suggest that there might exist several morphine receptors. 88 . 89 The possibility exists that the specific antinociceptive narcotic may be able to be synthesized, with little effect on gut receptors or postulated respiratory depression and euphoria receptors.
Non-narcotic analgetics:
It has been shown that several other neurotransmitter systems are involved in the nociceptive loop in addition to opioids. Intrathecal serotonin, noradrenaline, baclofen and capsaicin produce analgesia. Again, the clinical place of these compounds, or of pharmacological manipulation of them, awaits clarification.
SPECULATIONS
Intrathecal and epidural administration of narcotics is now established but the indications, advantages and disadvantages of the techniques are still being evaluated. What is the place in management of acute pain (surgical, obstetrical)? What is the optimal dose? (At what dose are receptors fully occupied?) How rapidly does tolerance develop?90 Can it be delayed or prevented? Is a reservoir or depot system feasible? Are there "better" opiates? What is the place in diagnosis of chronic pain? (i.e., if intrathecal narcotic does not relieve pain, does the pain arise from a structure rostral to the spinal cord?). Is it possible to use non-narcotic analgetics clinically? What pharmacological modifications of the system are feasible?91 It is clear that a great deal of research, basic and clinical, needs to be done to answer these questions.
